Joseph Jurcic, MD
Columbia University · Columbia University/Herbert Irving Cancer Center · Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Joseph Jurcic, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:34 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05524857 · Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)Joseph Jurcic · terminated · Myeloproliferative Neoplasm · principal investigator
- Ph1NCT03705858 · Actinium-225-Lintuzumab in Patients With Acute Myeloid LeukemiaJoseph Jurcic · withdrawn · Acute Myeloid Leukemia · principal investigator
- Ph1NCT02891278 · Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AMLColumbia University · completed · Acute Myeloid Leukemia · principal investigator
- Ph2NCT00780598 · Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AMLChroma Therapeutics · completed · Acute Myeloid Leukemia, AML · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in acute myeloid leukemia.